Synthetic RNA Therapeutics in Cancer
The Journal of Pharmacology and Experimental Therapeutics · 2023-08 · 386 (2) · 212-223
DOI: 10.1124/jpet.123.001587 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Journal of Pharmacology and Experimental Therapeutics, 2023-08. Verfasst von Youngjin Han und 5 weiteren Autor:innen. Beteiligte Einrichtung: Hanmi Research Center, Hanmi Pharmaceutical Co. Ltd., Gyeonggi-do, Republic of Korea (Y.H., S.-H.S., C.G.L., Y.H.H., I.Y.C.); and Biotherapeutics and…. Hauptthemen laut MEDLINE: MicroRNAs, Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 132 Literaturangaben.
Abstract (Originalsprache)
Recent advances in the RNA delivery system have facilitated the development of a separate field of RNA therapeutics, with modalities including mRNA, microRNA (miRNA), antisense oligonucleotide (ASO), small interfering RNA, and circular (circRNA) that have been incorporated into oncology research. The main advantages of the RNA-based modalities are high flexibility in designing RNA and rapid production for clinical screening. It is challenging to eliminate tumors by tackling a single target in cancer. In the era of precision medicine, RNA-based therapeutic approaches potentially constitute suitable platforms for targeting heterogeneous tumors that possess multiple sub-clonal cancer cell populations. In this review, we discussed how synthetic coding and non-coding RNAs, such as mRNA, miRNA, ASO, and circRNA, can be applied in the development of therapeutics. SIGNIFICANCE STATEMENT: With development of vaccines against coronavirus, RNA-based therapeutics have received attention. Here, the authors discuss different types of RNA-based therapeutics potentially effective against tumor that are highly heterogeneous giving rise to resistance and relapses to the conventional therapeutics. Moreover, this study summarized recent findings suggesting combination approaches of RNA therapeutics and cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Hanmi Research Center, Hanmi Pharmaceutical Co. Ltd., Gyeonggi-do, Republic of Korea (Y.H., S.-H.S., C.G.L., Y.H.H., I.Y.C.); and Biotherapeutics and Glycomics Laboratory, College of Pharmacy (Y.H.H., H.H.K.) and Depart…
Zitieren
APA
Han, Y., Shin, S. H., Lim, C. G., Heo, Y. H., Choi, I. Y., & Kim, H. H. (2023). Synthetic RNA Therapeutics in Cancer. The Journal of Pharmacology and Experimental Therapeutics, 386(2), 212-223. https://doi.org/10.1124/jpet.123.001587
Vancouver
Han Y, Shin SH, Lim CG, Heo YH, Choi IY, Kim HH. Synthetic RNA Therapeutics in Cancer. The Journal of Pharmacology and Experimental Therapeutics. 2023;386(2):212-223. doi:10.1124/jpet.123.001587
BibTeX
@article{Han2023,
author = {Han, Youngjin and Shin, Seung-Hyun and Lim, Chang Gyu and Heo, Yong Ho and Choi, In Young and Kim, Ha Hyung},
title = {Synthetic RNA Therapeutics in Cancer},
journal = {The Journal of Pharmacology and Experimental Therapeutics},
year = {2023},
volume = {386},
number = {2},
pages = {212--223},
doi = {10.1124/jpet.123.001587}
}
EUVIMED